TERAPIJSKI ODGOVOR BOLESNIKA SA CD30+ LIMFOMIMA NA PRIMENU BIOLOŠKE TERAPIJE

Jelena Cakic; Irena  Đunić

doi:10.5937/mp71-25438

Jelena Cakic Medicinski fakultet u Beogradu
Irena Đunić Klinika za hematologiju Kliničkog Centra Srbije, Medicinski fakultet Univerziteta u Beogradu

DOI: https://doi.org/10.5937/mp71-25438

Ključne reči: Hodgkin limfom, Brentuksimab vedotin, efikasnost terapije

Sažetak

Uvod: Poboljšanja u kombinovanoj hemioterapiji i radioterapiji novodijagnostikovanog Hodgkin-ovog limfoma (HL) rezultirala su trajnim stopama remisije od približno 60% do 80%. Međutim, oko 5% ranih stadijuma bolesti i 30% do 40% uznapredovalih bolesti dožive relaps nakon inicijalne hemioterapije. Standard u terapiji bolesnika sa relapsom ili refraktornim HL je hemioterapija spašavanja (salvage terapija) nakon koje sledi autologna transplantacija matičnih ćelija (ASCT). Kod otprilike 50% ovih bolesnika javlja se relaps bolest nakon ASCT kada mogućnosti lečenja postaju ograničene. Brentuximab vedotin (Adcetris®) je novi konjugat antitelo-lek koji dovodi do visokog odgovora kod CD30+ limfoma nakon ASCT.

Materijal i metode: U retrospektivnoj studiji ispitivano je 20 bolesnika, prosečne starosti 24,65 godina, obolelih od Hodgkin i Non-Nodgkin limfoma i lečenih biološkom terapijom na Klinici za hematologiju, Kliničkog centra Srbije, u periodu od 2002. do 2018. godine. Na osnovu informacija o bolesnicima dobijenih iz istorija bolesti formirane su baze podataka. Statistička analiza podataka obuhvatala je metode deskriptivne statistike i urađena je u SPSS programu.

Rezultati: Stopa objektivnog odgovora bila je 76,5% (CR+PR) sa postignutih 29,4% kompletnih remisija (CR) i 47,1% parcijalnih remisija (PR). Progresija bolesti zabeležena je kod 17,6% bolesnika. Medijana dužine trajanja terapijskog odgovora na BV bila je 9 meseci.

Zaključak: Primena biološke terapije dovela je do značajanog napretka u lečenju relapsa/refraktarnog Hodgkin-ovog limfoma, ali je efikasnije primeniti je kao ranu konsolidacionu terapiju odmah nakon ASCT, u cilju boljih rezultata lečenja ovih bolesnika.

Ključne reči: Hodgkin limfom, Brentuksimab vedotin, efikasnost terapije

Reference

1. Connors JM. State-of-the-art therapeutics: Hodgkin's lymphoma. J Clin Oncol. 2005;23:6400–6408.

2. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003;348:2386–2395.

3. Sureda A, Constans M, Iriondo A, et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol. 2005;16:625–633.

4. Majhail NS, Weisdorf DJ, Defor TE, et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2006;12:1065–1072.

5. Sureda A, Constans M, Iriondo A, et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol. 2005;16(4):625-33.

6. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin 2012;62:10–29.

7. Kuruvilla J. Standard therapy of advanced Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2009;97–506.

8. Arai S, Fanale M, DeVos S, et al. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma. 2013;54(11):2531-3.

9. Dürkop H, Latza U, Hummel M, et al. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell. 1992;68:421–427.

10. Falini B, Pileri S, Pizzolo G, et al. CD30 (Ki-1) molecule: A new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood. 1995;85:1–14.

11. Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed–Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985;66:848–58.

12. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102:1458–1465.

13. Younes A, Gopal AK, Smith SE, et al. Results of a Pivotal Phase 2 Study of Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin's Lymphoma. J Clin Oncol. 2012;30:2183-9.

14. Deng C, Pan B, O'Connor OA. Brentuximab vedotin. Clin Cancer Res. 2013;19(1):22-7.

15. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812-21

16. Fedele R, Martino M, Recchia AG, et al. Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review. J Immunol Res. 2015;2015:968212

17. Moskowitz CH, Walewski J, Nademanee A, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132(25):2639-2642.

18. Chen R, Palmer JM, Martin P, et al. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2015;21(12):2136-2140.

19. LaCasce AS, Bociek RG, Sawas A, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018;132(1):40-48.